First Analysis News
First Analysis invests in Lender Price, a leader in lending technology
First Analysis, a leading venture capital investor, has made a new investment in Lender Price. Lender Price’s cloud-based solutions help banks, mortgage bankers and mortgage brokers increase volumes and profitability, benefit from workflow efficiencies and improve their market competitiveness. The investment, led by longtime First Analysis partner Argentum Group, will further accelerate Lender Price’s rapid growth by supporting product development, sales and marketing and customer service capabi
October 15, 2021
First Analysis, a leading venture capital investor, has made a new investment in Lender Price. Lender Price’s cloud-based solutions help banks, mortgage bankers and mortgage brokers increase volumes and profitability, benefit from workflow efficiencies and improve their market competitiveness. The investment, led by longtime First Analysis partner Argentum Group, will further accelerate Lender Price’s rapid growth by supporting product development, sales and marketing and customer service capabi
October 15, 2021
First Analysis acted as the exclusive financial advisor to Selerix Systems for its investment by NexPhase Capital
First Analysis acted as the exclusive financial advisor to Selerix in securing an investment from NexPhase Capital. Selerix produces software used by employers, brokers and carriers to simplify benefits administration, employee engagement and Affordable Care Act (ACA) reporting. The terms of the transaction were not disclosed.
August 26, 2021
First Analysis acted as the exclusive financial advisor to Selerix in securing an investment from NexPhase Capital. Selerix produces software used by employers, brokers and carriers to simplify benefits administration, employee engagement and Affordable Care Act (ACA) reporting. The terms of the transaction were not disclosed.
August 26, 2021
First Analysis acted as the exclusive financial advisor to Healthify in its sale to WellSky®
First Analysis acted as the exclusive financial advisor to Healthify in its sale to WellSky, a leading health and community care technology company. Healthify improves the health of communities by connecting healthcare organizations with social service organizations to address the social determinants of health (SDoH). Healthify's past investors include SV Health Investors, Sandbox Ventures, Activate Venture Partners, Primary Venture Partners and Acumen. The terms of the transaction were not disc
August 03, 2021
First Analysis acted as the exclusive financial advisor to Healthify in its sale to WellSky, a leading health and community care technology company. Healthify improves the health of communities by connecting healthcare organizations with social service organizations to address the social determinants of health (SDoH). Healthify's past investors include SV Health Investors, Sandbox Ventures, Activate Venture Partners, Primary Venture Partners and Acumen. The terms of the transaction were not disc
August 03, 2021
First Analysis portfolio company Waggl acquired by Perceptyx
Perceptyx, the leading employee listening and people analytics platform, has acquired First Analysis portfolio company Waggl, an employee feedback solution that crowdsources employee comments and ideas in real-time. First Analysis remains an investor in Perceptyx.
July 30, 2021
Perceptyx, the leading employee listening and people analytics platform, has acquired First Analysis portfolio company Waggl, an employee feedback solution that crowdsources employee comments and ideas in real-time. First Analysis remains an investor in Perceptyx.
July 30, 2021
First Analysis exits portfolio company 4G Clinical as part of $230 million transaction
First Analysis, a leading venture capital investor, recently successfully exited its investment in portfolio company 4G Clinical, a leader in randomization and clinical trial supply management (RTSM) technology, as part of a more than $230 million growth equity investment by Goldman Sachs Asset Management. The investment will be used to fund 4G Clinical's continued global expansion, support the growing demand for 4G's products, and to further the company's mission of bringing crucial medicines t
July 21, 2021
First Analysis, a leading venture capital investor, recently successfully exited its investment in portfolio company 4G Clinical, a leader in randomization and clinical trial supply management (RTSM) technology, as part of a more than $230 million growth equity investment by Goldman Sachs Asset Management. The investment will be used to fund 4G Clinical's continued global expansion, support the growing demand for 4G's products, and to further the company's mission of bringing crucial medicines t
July 21, 2021
First Analysis acted as the exclusive financial advisor to Kno2 for its $15 million Series A funding co-led by Providence Ventures and Health Enterprise Partners
First Analysis acted as the exclusive financial advisor to Kno2 for its $15 million Series A funding round. Kno2 enables interoperability at scale across every patient care setting with the capability to send, receive, find and use patient information with everyone. The funding round was led by Health Enterprise Partners (HEP) and Providence Ventures.
July 15, 2021
First Analysis acted as the exclusive financial advisor to Kno2 for its $15 million Series A funding round. Kno2 enables interoperability at scale across every patient care setting with the capability to send, receive, find and use patient information with everyone. The funding round was led by Health Enterprise Partners (HEP) and Providence Ventures.
July 15, 2021
First Analysis acted as the exclusive financial advisor to SymphonyRM for its $25 million Series B funding led by TT Capital Partners
First Analysis acted as the exclusive financial advisor to SymphonyRM for its $25 million Series B funding. SymphonyRM transforms healthcare providers into member-focused enterprises through its innovative HealthOS platform. The round was led by new investment partner TT Capital Partners with continued investment from Adams Street Partners.
May 20, 2021
First Analysis acted as the exclusive financial advisor to SymphonyRM for its $25 million Series B funding. SymphonyRM transforms healthcare providers into member-focused enterprises through its innovative HealthOS platform. The round was led by new investment partner TT Capital Partners with continued investment from Adams Street Partners.
May 20, 2021
First Analysis invests in SmartCommerce, a leading frictionless e-commerce solution
First Analysis, a leading venture capital investor, has made a new investment in SmartCommerce. SmartCommerce provides data-centric, AI-assisted SaaS solutions for consumer packaged goods (CPG) companies. The $13 million round, led by longtime First Analysis partner Argentum Group, will be used for sales and marketing and continued product development.
April 21, 2021
First Analysis, a leading venture capital investor, has made a new investment in SmartCommerce. SmartCommerce provides data-centric, AI-assisted SaaS solutions for consumer packaged goods (CPG) companies. The $13 million round, led by longtime First Analysis partner Argentum Group, will be used for sales and marketing and continued product development.
April 21, 2021
First Analysis invests in Visage, a leading AI-powered talent recruiting platform
First Analysis, a leading venture capital investor, has made a new investment in Visage. Visage is a recruiting technology platform that combines the power of artificial intelligence (AI) and a freelance network to enable its customers to source talent more rapidly, effectively and cheaply than with any other technology, freeing recruiters to spend more time with candidates. First Analysis led the $7 million round.
March 19, 2021
First Analysis, a leading venture capital investor, has made a new investment in Visage. Visage is a recruiting technology platform that combines the power of artificial intelligence (AI) and a freelance network to enable its customers to source talent more rapidly, effectively and cheaply than with any other technology, freeing recruiters to spend more time with candidates. First Analysis led the $7 million round.
March 19, 2021
First Analysis acted as the exclusive financial advisor to Enli in its sale to Cedar Gate Technologies
First Analysis acted as the exclusive financial advisor to Enli Health Intelligence (Enli) in its sale to Cedar Gate Technologies (Cedar Gate). First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Enli. The First Analysis team was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
January 21, 2021
First Analysis acted as the exclusive financial advisor to Enli Health Intelligence (Enli) in its sale to Cedar Gate Technologies (Cedar Gate). First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Enli. The First Analysis team was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
January 21, 2021
First Analysis invests in insurtech company PCMI
First Analysis, a leading venture capital investor, has made a new investment in PCMI, a leading provider of administration software for the automotive, consumer and industrial warranty and service management markets. The round was led by Boston-based growth equity firm Equality Asset Management and enables PCMI to continue its focus on product expansion and client acquisition in North America and globally.
January 20, 2021
First Analysis, a leading venture capital investor, has made a new investment in PCMI, a leading provider of administration software for the automotive, consumer and industrial warranty and service management markets. The round was led by Boston-based growth equity firm Equality Asset Management and enables PCMI to continue its focus on product expansion and client acquisition in North America and globally.
January 20, 2021
First Analysis acted as the exclusive financial advisor in PCMI’s equity investment
First Analysis acted as the exclusive financial advisor to PCMI Corporation in its first equity investment. PCMI is a leading provider of administration software for the automotive, consumer and industrial warranty and service management markets. The equity investment was led by Boston-based growth equity firm Equality Asset Management. Financial terms were not disclosed.
January 20, 2021
First Analysis acted as the exclusive financial advisor to PCMI Corporation in its first equity investment. PCMI is a leading provider of administration software for the automotive, consumer and industrial warranty and service management markets. The equity investment was led by Boston-based growth equity firm Equality Asset Management. Financial terms were not disclosed.
January 20, 2021
First Analysis portfolio company NimbeLink acquired by Airgain
Airgain Inc. (Nasdaq: AIRG), a leading provider of advanced antenna technologies used to enable high performance wireless networking across a broad range of devices and markets, including consumer, enterprise and automotive, recently announced it has acquired First Analysis portfolio company NimbeLink, a leader in cellular industrial Internet of Things (IoT) solutions and services. The addition of NimbeLink’s embedded modem products and asset tracking solutions is key to Airgain’s ongoing strate
January 14, 2021
Airgain Inc. (Nasdaq: AIRG), a leading provider of advanced antenna technologies used to enable high performance wireless networking across a broad range of devices and markets, including consumer, enterprise and automotive, recently announced it has acquired First Analysis portfolio company NimbeLink, a leader in cellular industrial Internet of Things (IoT) solutions and services. The addition of NimbeLink’s embedded modem products and asset tracking solutions is key to Airgain’s ongoing strate
January 14, 2021
First Analysis portfolio company Apixio acquired by Centene
Centene Corp. (CNC) has acquired First Analysis portfolio company Apixio, a healthcare analytics company offering artificial intelligence technology solutions. First Analysis has a long history of researching and investing in healthcare technology companies. First Analysis Managing Director Matthew Nicklin commented, “We appreciate having had the opportunity to be part of the Apixio story. Apixio is a great example of how a strong team addressing a critical need in the healthcare ecosystem can c
December 09, 2020
Centene Corp. (CNC) has acquired First Analysis portfolio company Apixio, a healthcare analytics company offering artificial intelligence technology solutions. First Analysis has a long history of researching and investing in healthcare technology companies. First Analysis Managing Director Matthew Nicklin commented, “We appreciate having had the opportunity to be part of the Apixio story. Apixio is a great example of how a strong team addressing a critical need in the healthcare ecosystem can c
December 09, 2020
First Analysis acted as the exclusive financial advisor to Kazmira for its minority equity investment from Perrigo
First Analysis acted as the exclusive financial advisor to Kazmira for its $50 million strategic investment by Perrigo Company (PRGO). In collaboration with Perrigo, the investment will be applied to scale up Kazmira’s facilities and laboratories, proactively engage with regulatory authorities, further develop Kazmira’s product portfolio, extend Kazmira’s reach into retail mass markets, and enhance Kazmira’s strong management and technical teams.
August 24, 2020
First Analysis acted as the exclusive financial advisor to Kazmira for its $50 million strategic investment by Perrigo Company (PRGO). In collaboration with Perrigo, the investment will be applied to scale up Kazmira’s facilities and laboratories, proactively engage with regulatory authorities, further develop Kazmira’s product portfolio, extend Kazmira’s reach into retail mass markets, and enhance Kazmira’s strong management and technical teams.
August 24, 2020
First Analysis invests in Fortress Information Security, a risk management solution provider
First Analysis, a leading venture capital investor, has made a new investment in Fortress Information Security, an information security and cyber risk mitigation company that has redefined traditional risk management. Fortress combines automation, continuous monitoring, vulnerability scanning and other powerful technology with human assets to deliver risk management solutions for critical infrastructure clients such as electric utilities.
August 04, 2020
First Analysis, a leading venture capital investor, has made a new investment in Fortress Information Security, an information security and cyber risk mitigation company that has redefined traditional risk management. Fortress combines automation, continuous monitoring, vulnerability scanning and other powerful technology with human assets to deliver risk management solutions for critical infrastructure clients such as electric utilities.
August 04, 2020
First Analysis acted as the exclusive financial advisor to sticky.io for its minority equity investment
First Analysis acted as the exclusive financial advisor to sticky.io (formerly LimeLight CRM) for its capital financing led by Flexpoint Ford. The First Analysis team worked closely with sticky.io to understand the industry and create a unit-based economic model while positioning the company optimally in the marketplace.
July 02, 2020
First Analysis acted as the exclusive financial advisor to sticky.io (formerly LimeLight CRM) for its capital financing led by Flexpoint Ford. The First Analysis team worked closely with sticky.io to understand the industry and create a unit-based economic model while positioning the company optimally in the marketplace.
July 02, 2020
First Analysis announces enhanced cutting-edge research focus
As First Analysis approaches its 40th year of using integrative research to uncover and leverage the best opportunities in emerging high-growth segments in technology and healthcare, it is enhancing its research model and increasing its commitment to publishing research on cutting-edge trends in technology and healthcare.
April 22, 2020
As First Analysis approaches its 40th year of using integrative research to uncover and leverage the best opportunities in emerging high-growth segments in technology and healthcare, it is enhancing its research model and increasing its commitment to publishing research on cutting-edge trends in technology and healthcare.
April 22, 2020
First Analysis invests in VIDA, the leader in AI-powered lung imaging analysis
First Analysis, a leading venture capital investor, has made a new investment in VIDA Diagnostics Inc. (VIDA). VIDA provides the new standard of pulmonary care by using AI-powered CT imaging software and services to aid early detection, evaluation, and treatment planning for patients with or at risk of lung diseases. First Analysis led an $11 million initial close of the Series C round to accelerate the commercialization of VIDA’s LungPrint® solution suite.
March 17, 2020
First Analysis, a leading venture capital investor, has made a new investment in VIDA Diagnostics Inc. (VIDA). VIDA provides the new standard of pulmonary care by using AI-powered CT imaging software and services to aid early detection, evaluation, and treatment planning for patients with or at risk of lung diseases. First Analysis led an $11 million initial close of the Series C round to accelerate the commercialization of VIDA’s LungPrint® solution suite.
March 17, 2020
First Analysis invests in innovative eClinical solution provider 4G Clinical
First Analysis, a leading venture capital investor, has made a new minority investment in 4G Clinical. 4G Clinical is a global leader in randomization and trial supply management (RTSM) for the life sciences industry. First Analysis participated in the investment along with existing investors.
January 29, 2020
First Analysis, a leading venture capital investor, has made a new minority investment in 4G Clinical. 4G Clinical is a global leader in randomization and trial supply management (RTSM) for the life sciences industry. First Analysis participated in the investment along with existing investors.
January 29, 2020
New First Analysis white paper: Going beyond the pill
First Analysis Vice President Joseph Munda’s latest white paper explores the dynamic and rapidly evolving array of digital technology solutions related to drug commercialization. Munda highlights numerous promising opportunities in this burgeoning emerging sector. His work builds on his broad involvement in medical and pharmaceutical technology as well as his 2018 white paper, “eClinical Solutions: Streamlining the introduction of new drugs and medical technology.”
January 13, 2020
First Analysis Vice President Joseph Munda’s latest white paper explores the dynamic and rapidly evolving array of digital technology solutions related to drug commercialization. Munda highlights numerous promising opportunities in this burgeoning emerging sector. His work builds on his broad involvement in medical and pharmaceutical technology as well as his 2018 white paper, “eClinical Solutions: Streamlining the introduction of new drugs and medical technology.”
January 13, 2020
First Analysis welcomes Andrew Walsh to its Investment Banking Group
Chicago-based First Analysis Securities Corporation announced Andrew Walsh has joined the firm as a Managing Director. This move expands First Analysis's investment banking practice and its commitment to advising premier companies in the firm's healthcare sector.
January 09, 2020
Chicago-based First Analysis Securities Corporation announced Andrew Walsh has joined the firm as a Managing Director. This move expands First Analysis's investment banking practice and its commitment to advising premier companies in the firm's healthcare sector.
January 09, 2020
First Analysis portfolio company Checkpoint Surgical receives FDA breakthrough designation for nerve regeneration device
First Analysis portfolio company Checkpoint Surgical, a leader in hand-held, intraoperative neurostimulation technology for nerve protection and repair, announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Checkpoint brief electrostimulation therapy (BEST) system.
September 17, 2019
First Analysis portfolio company Checkpoint Surgical, a leader in hand-held, intraoperative neurostimulation technology for nerve protection and repair, announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Checkpoint brief electrostimulation therapy (BEST) system.
September 17, 2019
First Analysis leads investment in video telematics solution provider SmartWitness
First Analysis, a leading venture capital investor, has made a new investment in SmartWitness, an end-to-end video telematics solutions provider that offers hardware, network connectivity, and robust cloud platform software.
August 27, 2019
First Analysis, a leading venture capital investor, has made a new investment in SmartWitness, an end-to-end video telematics solutions provider that offers hardware, network connectivity, and robust cloud platform software.
August 27, 2019
First Analysis Acted as Exclusive Financial Advisor to Built In for its $22 million Series C Financing Led by Updata Partners
Updata Partners led the round, with participation from existing investors including MATH Venture Partners, which led Built In's previous two funding rounds.
August 01, 2019
Updata Partners led the round, with participation from existing investors including MATH Venture Partners, which led Built In's previous two funding rounds.
August 01, 2019
First Analysis leads investment in restaurant management technology platform SynergySuite
First Analysis, a leading venture capital investor, has made a new investment in SynergySuite, a cloud-based restaurant management platform. First Analysis led a $6 million Series A round to support growth in the U.S. market and product innovation.
July 16, 2019
First Analysis, a leading venture capital investor, has made a new investment in SynergySuite, a cloud-based restaurant management platform. First Analysis led a $6 million Series A round to support growth in the U.S. market and product innovation.
July 16, 2019
First Analysis leads investment in smart charger technology leader Current Ways
First Analysis, a leading venture capital investor, has made a new investment in Current Ways, a company with operations mainly in California that specializes in power conversion, communication, and battery charging applications.
July 02, 2019
First Analysis, a leading venture capital investor, has made a new investment in Current Ways, a company with operations mainly in California that specializes in power conversion, communication, and battery charging applications.
July 02, 2019
First Analysis welcomes Terry Kiwala and Logan Bender to its investment team
Terry Kiwala and Logan Bender have joined Chicago-based First Analysis’s venture capital investment and research team.
June 04, 2019
Terry Kiwala and Logan Bender have joined Chicago-based First Analysis’s venture capital investment and research team.
June 04, 2019
First Analysis portfolio company Chrome River Technologies merges with Certify
Certify Inc., the world’s largest independent provider of travel, expense, and invoice management software, has merged with First Analysis portfolio company Chrome River Technologies, which provides cloud-based expense and invoice automation solutions for more than 1,000 organizations worldwide.
March 26, 2019
Certify Inc., the world’s largest independent provider of travel, expense, and invoice management software, has merged with First Analysis portfolio company Chrome River Technologies, which provides cloud-based expense and invoice automation solutions for more than 1,000 organizations worldwide.
March 26, 2019
First Analysis leads investment in global digital risk protection company AppDetex
First Analysis, a leading venture capital investor, has made a new investment in Boise, Idaho, based AppDetex, leading its $10 million Series B equity financing to expand sales and marketing and to invest in product development.
March 20, 2019
First Analysis, a leading venture capital investor, has made a new investment in Boise, Idaho, based AppDetex, leading its $10 million Series B equity financing to expand sales and marketing and to invest in product development.
March 20, 2019
First Analysis acted as the Exclusive Financial Advisor to PrescribeWellness in its sale to Tabula Rasa HealthCare
First Analysis provided advisory expertise to PrescribeWellness throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
March 07, 2019
First Analysis provided advisory expertise to PrescribeWellness throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
March 07, 2019
First Analysis acted as the Exclusive Financial Advisor to Mirixa in its sale to Cardinal Health
First Analysis acted as the exclusive financial advisor in the sale of Mirixa, a leading healthcare technology and services company specializing in medication therapy management (MTM).
January 10, 2019
First Analysis acted as the exclusive financial advisor in the sale of Mirixa, a leading healthcare technology and services company specializing in medication therapy management (MTM).
January 10, 2019
First Analysis Acted as the Exclusive Financial Advisor to ClearCompany for $60 Million Minority Growth Equity Investment
First Analysis acted as the exclusive financial advisor to ClearCompany for its $60 million growth capital financing round led by Primus Capital.
August 20, 2018
First Analysis acted as the exclusive financial advisor to ClearCompany for its $60 million growth capital financing round led by Primus Capital.
August 20, 2018
First Analysis closes on new $91 million private growth equity fund
First Analysis, a leading mid-stage venture capital investor, has closed on its 13th fund (First Analysis Fund XII+) at $91 million in committed capital. With the new fund, First Analysis will continue its 33-year track record in technology and healthcare investing. To date, the fund has invested in three companies.
July 10, 2018
First Analysis, a leading mid-stage venture capital investor, has closed on its 13th fund (First Analysis Fund XII+) at $91 million in committed capital. With the new fund, First Analysis will continue its 33-year track record in technology and healthcare investing. To date, the fund has invested in three companies.
July 10, 2018
First Analysis leverages human capital tech expertise as co-manager on Pluralsight IPO
First Analysis recently acted as co-manager for Pluralsight Inc.'s $311 million initial public offering. Pluralsight is an enterprise technology learning platform that delivers a unified, end-to-end learning experience for businesses across the globe.
June 27, 2018
First Analysis recently acted as co-manager for Pluralsight Inc.'s $311 million initial public offering. Pluralsight is an enterprise technology learning platform that delivers a unified, end-to-end learning experience for businesses across the globe.
June 27, 2018
First Analysis Acted as the Exclusive Financial Advisor for the Growth Equity Investment in FairWarning
First Analysis acted as the exclusive financial advisor for Mainsail Partners’ $60 million growth equity investment in FairWarning LLC, a leader in data protection and governance solutions. First Analysis provided advisory expertise to FairWarning throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
June 13, 2018
First Analysis acted as the exclusive financial advisor for Mainsail Partners’ $60 million growth equity investment in FairWarning LLC, a leader in data protection and governance solutions. First Analysis provided advisory expertise to FairWarning throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
June 13, 2018
©2021 by First Analysis Corporation.
One South Wacker Drive
  ·  
Suite 3900
  ·  
Chicago, IL 60606
  ·  
312-258-1400